- Home
- MDGL vs ELS Comparison
MDGL vs ELS Comparison
Compare MDGL & ELS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MDGL | ELS |
|---|---|---|
| Founded | 2011 | 1992 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.0B | 13.2B |
| IPO Year | 2005 | 1994 |
Fundamental Metrics
Financial Performance| Metric | MDGL | ELS |
|---|---|---|
| Price | $521.03 | $63.87 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 12 | 10 |
| Target Price | ★ $674.45 | $70.85 |
| AVG Volume (30 Days) | 349.8K | ★ 1.2M |
| Earning Date | 04-30-2026 | 04-20-2026 |
| Dividend Yield | N/A | ★ 3.39% |
| EPS Growth | ★ 41.32 | 2.55 |
| EPS | N/A | ★ 2.01 |
| Revenue | $180,133,000.00 | ★ $1,531,382,000.00 |
| Revenue This Year | $58.39 | $3.97 |
| Revenue Next Year | $47.10 | $4.69 |
| P/E Ratio | ★ N/A | $31.87 |
| Revenue Growth | N/A | ★ 0.34 |
| 52 Week Low | $265.00 | $57.63 |
| 52 Week High | $615.00 | $69.00 |
Technical Indicators
Market Signals| Indicator | MDGL | ELS |
|---|---|---|
| Relative Strength Index (RSI) | 62.15 | 44.91 |
| Support Level | $411.87 | $58.56 |
| Resistance Level | $610.00 | $68.73 |
| Average True Range (ATR) | 26.99 | 1.00 |
| MACD | 3.75 | 0.10 |
| Stochastic Oscillator | 64.35 | 66.45 |
Price Performance
Historical ComparisonAbout MDGL Madrigal Pharmaceuticals Inc.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, liver cancer, need for liver transplantation and premature mortality. Its medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor beta agonist designed to target key underlying causes of MASH.
About ELS Equity Lifestyle Properties Inc.
Equity Lifestyle Properties is a residential REIT that focuses on owning manufactured housing, residential vehicle communities, and marinas. The company currently has a portfolio of 455 properties across the US with a higher concentration in the Sunbelt; 38% of the company's properties are in Florida, 12% in Arizona, and 8% in California. Equity Lifestyle targets owning properties in attractive retirement destinations. More than 70% of the company's properties are either age-restricted or have an average resident age over 55.